The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Mergers and acquisitions in the pharmaceutical and biotech industries
Abstract
We examine the determinants and effects of M&A activity in the pharmaceutical/biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large firms, mergers are a response to expected excess capacity due to patent expirations and gaps in a firm's product pipeline. For small firms, mergers are primarily an exit strategy in response to financial trouble (low Tobin's q, few marketed products, low cash–sales ratios). In estimating effects of mergers, we use a propensity score to control for selection based on observed characteristics. Controlling for merger propensity, large firms that merged experienced a similar change in enterprise value, sales, employees, and R&D, and had slower growth in operating profit, compared with similar firms that did not merge. Thus mergers may be a response to trouble, but they are not a solution. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effectiveness of Adjustment by Subclassification in Removing Bias in Observational Studies
Cochran, W. G. (1968) · Biometrics · doi:10.2307/2528036 · Cited by 961
Cited by
Corporate Innovations and Mergers and Acquisitions
BENA, J., & LI, K. (2014) · The Journal of Finance · doi:10.1111/jofi.12059 · Cited by 869
The cost of drug development: A systematic review
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011) · Health Policy · doi:10.1016/j.healthpol.2010.12.002 · Cited by 510
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
Metadata
- Authors
- Danzon, P. M., Epstein, A., & Nicholson, S.
- Venue
- Managerial and Decision Economics
- Publisher
- Wiley
- Published
- 2007-06
- Volume
- 28
- Issue
- 4-5
- Pages
- 307-328
- ISSN
- 0143-6570 (ISSN-L)
- 1099-1468
- OpenAlex
- W3125487025
- Cited by
- 236
- References
- 1
- FWCI
- 26.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.